Fudan University

This study tests a personalized vaccine created from a patient's own immune cells (dendritic cells) that are trained to attack unique markers on their tumor. It is for people with advanced solid tumors who have not responded to standard treatments. The main goal is to check safet…

This phase 3 trial compares an all-oral drug combination (pyrotinib, trastuzumab, and dalpiciclib) against standard chemotherapy plus targeted drugs for advanced HER2-positive breast cancer. About 502 patients who have had at most one prior treatment will be enrolled. The goal is…

This phase 3 trial tests whether adding chemotherapy to standard radiotherapy after complete surgical removal of thymic cancer can reduce the chance of the cancer coming back. About 172 adults aged 18-75 with early-stage thymic cancer will be randomly assigned to receive either r…

This early-phase trial tests two types of engineered immune cells (CAR-T and TCR-T) in 24 people with recurrent or treatment-resistant nasopharyngeal carcinoma that is linked to the Epstein-Barr virus. The cells are designed to recognize and attack the cancer. The main goals are …

This study aims to improve fertility-sparing treatment for young women (ages 18-45) with endometrial cancer by tailoring therapy to the tumor's genetic profile. Participants will receive either hormone therapy (progestins) or a combination with an immunotherapy drug (sintilimab),…

This Phase 2 trial is testing whether combining an experimental immunotherapy drug (SHR-1701) with targeted radiation can help men whose prostate cancer has spread and stopped responding to hormone therapy. About 66 participants will receive either the combination or radiation al…

This study is observing 150 adults with advanced liver cancer who are starting immunotherapy for the first time. Researchers will track how well different drug combinations shrink tumors and how the immune system changes. The goal is to learn which treatments work best and why, w…

This phase II trial is testing whether adding omega-3 fatty acid supplements to standard immunotherapy (PD-1 inhibitors) can help patients with advanced esophageal cancer. About 142 adults will be randomly assigned to receive either omega-3 or placebo drops daily for six months, …

This phase 2 trial tests a new drug called vebrekotuzumab, which delivers a powerful toxin directly to cancer cells that have a protein called EGFR. It is being tested alone or with an immunotherapy drug in 104 patients whose esophageal cancer has stopped responding to initial tr…

This phase 2 trial is testing a combination of four drugs—two chemotherapy drugs (gemcitabine and oxaliplatin), a targeted therapy (donafenib), and an immunotherapy (tislelizumab)—in 93 people with advanced biliary tract cancer that has spread. The goal is to see if this mix can …

This study tests whether adding precise radiation (SBRT) to a four-drug combination (sintilimab, bevacizumab, and chemotherapy) can help people with advanced EGFR-mutant lung cancer whose tumors have stopped responding to standard targeted therapy. About 53 participants will rece…

This early study tests a new cell therapy called RGL-305 in 12 lymphoma patients who still have traces of cancer after standard treatment. The therapy is given through an IV over several cycles. The main goal is to check if it is safe and how the cells behave in the body, not yet…

This study looks at whether giving radiation therapy within 6 weeks after surgery can help prevent thyroid cancer from coming back in people at high risk. It includes 80 patients with various types of thyroid cancer (except undifferentiated). The main goal is to see how long they…

This phase 3 trial is testing whether giving radiation only to the lower armpit lymph nodes works as well as giving radiation to a larger area of lymph nodes in breast cancer patients who have 1-2 positive sentinel nodes. The study plans to enroll 1608 women with early-stage brea…

This Phase 2 trial is testing an experimental immunotherapy drug called QL1706 combined with standard chemotherapy (nab-paclitaxel and gemcitabine), with or without another drug called bevacizumab, as a first treatment for people with advanced pancreatic cancer that cannot be rem…

This phase 2 trial is testing a combination of two drugs—deruxtecan (a targeted chemotherapy) and ivonescimab (an immunotherapy)—in people with hormone receptor-positive, HER2-negative advanced breast cancer. The study aims to see how well the combination shrinks tumors and how s…

This study is for people with early-stage natural killer/T-cell lymphoma, a rare and aggressive cancer often linked to EBV. It compares three different sequences of chemotherapy, immunotherapy, and radiation to see which one keeps the cancer from coming back for at least two year…

This study tests whether adding a drug called IL-11 to the standard G-CSF can help blood cells recover faster after a stem cell transplant in people with blood cancers like multiple myeloma or lymphoma. About 224 adults will be randomly assigned to get either the combo or G-CSF a…

This study tests a drug called tunlametinib in people with advanced melanoma that has a specific NRAS gene change and has not responded to prior immunotherapy. About 110 adults will take the drug by mouth to see if it can shrink tumors and how safe it is. The goal is to control t…

This study tests whether the drug golidocitinib can help keep peripheral T-cell lymphoma (a rare blood cancer) from coming back after initial chemotherapy. About 136 adults who had a good response to first treatment but cannot or choose not to have a stem cell transplant will tak…

This study tests whether adding radiotherapy to a combination of chemotherapy (CAPOX) and an immunotherapy drug (Toripalimab) can improve outcomes for people with a specific type of locally advanced rectal cancer (MSS/pMMR). About 192 participants will receive either the drug com…

This study tests whether using a blood test that detects tumor DNA can help doctors decide how long chemotherapy should last for people with certain types of colorectal cancer. About 340 adults with stage II or low-risk stage III colorectal cancer will be randomly assigned to sta…

This study tests whether adding retinoic acid (a vitamin A derivative) to an immune checkpoint inhibitor can help shrink tumors or slow disease progression in people with HER2-negative breast cancer whose cancer stopped responding to prior immunotherapy. About 10 participants wil…

This study tests whether adding a special type of radiation (guided by a PET scan) and an immunotherapy drug to standard second-line treatment can shrink tumors better than standard treatment alone in people with colorectal cancer that has spread to the lining of the abdomen. Abo…

This study tests new drug combinations (ADC drugs alone or with other therapies) in 160 people with advanced pancreatic cancer that has spread or cannot be removed. The goal is to find safe doses and see if tumors shrink. Participants must be 18-75, in good overall health, and ha…

This study is for people with colorectal cancer that came back within a year after finishing initial chemotherapy. It tests whether adding an immunotherapy drug called serplulimab to standard second-line chemo and targeted therapy can help control the cancer longer. About 40 part…

This study tests whether adding a liver-directed chemotherapy infusion (HAIC) to a two-drug immunotherapy regimen (sintilimab plus bevacizumab) can better control advanced liver cancer. About 164 adults with liver cancer that cannot be removed by surgery or treated with local the…

This study tests a chemotherapy regimen (R-CDOP) plus a drug injected into the spine (intrathecal methotrexate) in 83 adults with untreated diffuse large B-cell lymphoma at high risk of spreading to the brain. The goal is to see if this combination lowers the chance of central ne…

This study tests a new combination of drugs (L-Ornithine L-Aspartate, N-Acetylcysteine, CDK4/6 inhibitors, and Fulvestrant) in 40 women with HR-positive/HER2-negative advanced breast cancer whose disease got worse after standard therapy. The goal is to see if the combo can shrink…

This study is testing whether using an indoor air purifier can improve lung health in people with Chronic Obstructive Pulmonary Disease (COPD). About 120 adults with COPD who live in Shanghai will use either a real air purifier or a placebo device in their homes for a period of t…

This study tests whether metformin, a diabetes drug, can improve mild memory and thinking problems in older adults who are overweight or obese. Fifty-four participants will receive either metformin plus lifestyle advice or lifestyle advice alone for 26 weeks. Researchers will use…

This phase 2 trial is testing several drug combinations (including choline, sodium cromoglicate, efavirenz, and others) alongside immunotherapy to see if they can reverse resistance in triple-negative breast cancer that has progressed after prior immunotherapy. About 80 participa…

This study is for people with HER2-negative breast cancer that has spread to the lining of the brain (leptomeningeal metastasis). It compares standard chemotherapy given through the veins or by mouth to the same treatment plus extra chemotherapy delivered directly into the spinal…

This phase 2 trial at Fudan University is testing several targeted drug combinations given before surgery for early-stage breast cancer. The goal is to see if matching drugs to the tumor's specific features can improve the rate of complete cancer clearance. About 716 participants…

This study tests whether adding a CDK4/6 inhibitor to standard hormone therapy can help prevent breast cancer from coming back in high-risk patients with HR+/HER2+ early breast cancer. About 1,900 women aged 18-70 who have already completed anti-HER2 therapy will be randomly assi…

This study tests whether giving treatments based on the genetic makeup of a person's triple-negative breast cancer can shrink tumors or slow the disease. It is for people whose cancer has not responded to standard therapies. About 120 women will receive a treatment chosen specifi…

This phase 3 trial tests whether adding an anti-vascular drug to standard chemotherapy can help prevent cancer from returning in people with a specific, aggressive type of triple-negative breast cancer. About 764 women with stage II to III cancer will receive either the combinati…

This study tests whether a combination of two drugs, sacituzumab tirumotecan and bevacizumab, can shrink or control brain tumors in people with triple-negative breast cancer that has spread to the brain. About 24 adults whose cancer cannot be removed by surgery or radiation will …

This study tests a daily pill called sunvozertinib in 34 people with advanced non-small cell lung cancer that has certain uncommon EGFR gene changes. Participants have not had prior cancer treatment. The goal is to see if the drug can shrink tumors and delay cancer growth. This i…

This study tests whether a combination of two hormone drugs (GnRHa and letrozole) works better than standard hormone pills (megestrol or medroxyprogesterone) to make early-stage endometrial cancer disappear while preserving the ability to have children. About 104 women with stage…

This study tests several new drug combinations for people with advanced liver cancer whose first treatment stopped working. It involves 350 adults and uses advanced imaging and genetic tests to find which treatment works best for each person. The goal is to shrink or control the …

This study looks at whether adding radiation therapy to the usual radioactive iodine treatment can help prevent thyroid cancer from coming back in people with high-risk, advanced thyroid cancer. About 124 adults who had surgery but still have some cancer left will be randomly ass…

This study tests a new drug (HRS-4642) combined with an immunotherapy (adebrelimab) and possibly other cancer drugs for people with advanced pancreatic cancer that has not responded to standard treatments. The goal is to find safe doses and see if the combination can shrink tumor…

This study tests a combination of two drugs, SKB264 and inetetamab, in people with HER2-positive breast cancer that has spread and is no longer responding to a standard treatment called T-DXd. The goal is to see if this new combination can shrink tumors or slow the cancer. About …

This study tests a new combination of drugs (tislelizumab, liposomal doxorubicin, and ifosfamide) as a first treatment for people with advanced soft tissue sarcoma that cannot be removed by surgery or has spread. The goal is to see if this combo shrinks tumors and is safe. About …

This study tests a two-step approach for people with liver metastases from triple-negative breast cancer, melanoma, or colorectal cancer. First, doctors use heat or cold to destroy some liver tumors, which may release cancer signals that train the immune system. Then, patients re…

This study tests whether a combination of three drugs (RC48, sintilimab, and SOX) can shrink advanced stomach cancer enough to allow surgical removal. It includes 30 adults with a specific type of HER2-positive cancer who have not had prior treatment. The goal is to see how many …

This study tests whether adding the drug VEGFR BP102 to standard chemotherapy (nab-paclitaxel) helps people with a specific, hard-to-treat form of advanced triple-negative breast cancer (called BLIS subtype). About 134 participants who have not had prior treatment for metastatic …

This study looks at different second-line treatments for people with advanced stomach or gastroesophageal junction cancer that has stopped responding to initial chemotherapy and immunotherapy. The goal is to find which drug combinations work best and are safest. About 250 adults …

This study tests a combination of two drugs, fruquintinib and serplulimab, in people with advanced colorectal cancer that has spread to places other than just the liver and has not responded to standard treatments. The goal is to see if this combination can shrink tumors or slow …

This study tests whether adding immunotherapy to a precise type of radiotherapy (sparing tumor-draining lymph nodes) and chemotherapy can help adults with advanced esophageal cancer live longer without the disease getting worse. About 432 participants will receive either the comb…

This study tests two drugs together—MRG003 and pucotenlimab—for people with a rare and aggressive type of thyroid cancer (ATC or PDTC) that has spread and cannot be removed by surgery. About 60 adults will receive the combination every three weeks. The main goal is to see if the …

This study tests a combination of an immune-boosting drug (TQB2450) and a high-dose hormone (progestin) to treat young women (ages 18-45) with a specific type of early-stage endometrial cancer (MMRd). The goal is to eliminate the cancer while preserving the uterus so patients can…

This study tests two experimental drugs, SHR-0302 and SHR-2554, given together to people with a rare type of blood cancer called peripheral T-cell lymphoma that has returned or not improved after prior treatment. The goal is to see if the combination is safe and can shrink or con…

This study is for people with high-risk stage III colorectal cancer. It tests whether using a blood test (ctDNA) to guide treatment decisions can improve outcomes. Participants will receive either standard chemotherapy or chemotherapy plus bevacizumab, with regular blood monitori…

This study tests a treatment plan for people with low rectal cancer that can be removed with surgery. Participants receive chemotherapy and an immunotherapy drug called tislelizumab before surgery. The goal is to see if this combination can make the cancer disappear completely, a…

This study tests whether adding immunotherapy (a drug that helps the immune system fight cancer) after standard chemotherapy and radiation can help people with advanced esophageal cancer live longer without the disease getting worse. About 452 adults with a specific type of esoph…

This study tests whether a new drug, serplulimab, combined with chemotherapy works better than the standard drug, nivolumab, plus chemotherapy for shrinking lung cancer before surgery. About 116 people with stage II to IIIa squamous non-small cell lung cancer will take part. The …

This study explores whether changes in a blood-based tumor marker (ctDNA) can help doctors decide the best treatment for people with HER2-negative metastatic breast cancer. Participants first receive a standard antibody-drug combination therapy. Based on how much the ctDNA level …

This study tests a new surgical technique called Q-ISR for people with ultra-low rectal cancer. It compares Q-ISR to two standard surgeries to see if it can better preserve bowel function while still controlling the cancer. About 100 adults with small tumors near the anal opening…

This study tests whether giving radiation only to the parts of the neck where cancer has spread works as well as treating the entire neck in people with nasopharyngeal carcinoma. About 462 adults with stage I–III disease will be randomly assigned to receive either standard or ind…

This study looks at whether a blood test that detects tumor DNA can help doctors decide which patients with early-stage colorectal cancer need stronger chemotherapy after surgery. About 80 patients whose blood tests show signs of remaining cancer one month after surgery will rece…

This study looks at whether giving a second course of antibody-drug conjugates (ADCs) can safely shrink tumors in people with advanced breast cancer who have already received these drugs. About 160 adults with metastatic breast cancer will receive the same or a different ADC and …

This study tests whether a transplant of donated umbilical cord blood can help people aged 14 to 80 with serious diseases caused by the Epstein-Barr virus (EBV), such as certain lymphomas or chronic active EBV infection. The goal is to control the disease and improve survival, bu…

This study tests whether adding a drug called narlumosbart and targeted radiation to standard chemotherapy and immunotherapy can improve treatment for advanced non-small cell lung cancer that has spread to the bones. The trial will enroll 27 adults who have not had prior treatmen…

This study tests two different treatment plans for people with locally advanced rectal cancer that has not spread. Both plans combine radiation, chemotherapy, an immunotherapy drug, and a pain reliever that may boost the immune response. The goal is to see which plan leads to a h…

This study looks at people with high-risk stage II colorectal cancer who have a positive blood test for cancer DNA one month after surgery. It aims to see if giving stronger chemotherapy based on that test can clear the cancer DNA and improve survival. About 340 participants will…

This study tests a drug called Becotatug vedotin in 40 adults with advanced liver cancer that has worsened after standard treatments. The goal is to see if it can shrink tumors and help control the disease. Participants receive the drug and are monitored for safety and response.

This study tests whether adding the immunotherapy drug sintilimab to standard chemotherapy (SOX) can help prevent stomach or gastroesophageal junction cancer from coming back after surgery. It includes 276 adults with high-risk or specific genetic types of cancer. Participants ar…

This study tests whether adding the drug cadonilimab (AK104) and radiation to standard chemotherapy helps people with colorectal cancer that has spread to the liver. About 73 adults who have not had treatment before will be randomly assigned to either the new combo or standard th…

This study tests a mix of radiation, chemotherapy, immunotherapy, and targeted drugs in 44 people whose rectal cancer has returned after prior treatment. The goal is to shrink tumors enough for possible surgery. Participants receive focused radiation and up to 8 cycles of the dru…

This study tests whether combining radiation therapy with three drugs (platinum chemotherapy, adebrelimab, and bevacizumab) can control brain metastases from triple-negative breast cancer. About 58 adults aged 18-70 with this specific type of advanced breast cancer will receive t…

This study tests a new approach for people with high-risk soft tissue sarcoma that has not spread. Before surgery, patients receive a combination of radiation, chemotherapy, and an immunotherapy drug (sintilimab). The goal is to shrink the tumor enough to make surgery more effect…

This study tests whether combining two drugs—sintilimab and chidamide—can help people with a rare type of lymphoma (peripheral T-cell lymphoma) that has returned or not responded to prior treatments. About 51 adults aged 18 to 75 will receive the drug combination. The goal is to …

This study tests whether adding probiotics (good bacteria) to standard chemoradiation and immunotherapy can help people with limited-stage small cell lung cancer live longer without the disease getting worse. About 60 adults aged 18-80 will take part. The goal is to see if this c…

This study tests a mix of three chemotherapy drugs (gemcitabine, cisplatin, nab-paclitaxel) plus an immunotherapy drug (durvalumab) in people with advanced gallbladder cancer that cannot be removed by surgery. The goal is to see if this combination shrinks tumors and how safe it …

This study looks at whether giving radiation therapy after completely removing a type of chest tumor called thymoma (stages II or III) helps prevent the cancer from coming back and improves survival. About 238 adults aged 18-75 who had surgery within the last 3 months will be ran…

This study tests two different radiation schedules (long-course vs short-course) combined with chemotherapy (CAPOX), an immunotherapy drug (PD-1 inhibitor), and a COX-2 inhibitor in people with a specific type of advanced rectal cancer (MSS type). The goal is to see which approac…

This study tests whether a smaller, more targeted neck surgery (selective neck dissection) works as well as the standard larger surgery (modified neck dissection) for people with papillary thyroid cancer that has spread to only 1 or 2 small lymph nodes in the side of the neck. Ab…

This study tests whether adding an immunotherapy drug (anti-PD-1) to standard chemoradiation can better control anal squamous cell cancer and reduce the chance of it coming back. It includes 241 adults aged 18-75 with different stages of the disease, from early to advanced or rec…

This study is testing a new blood test that looks for tiny particles from breast cancer cells, called small extracellular vesicles (sEVs), to determine the cancer's molecular subtype. The goal is to see if this test is as accurate as the standard tissue biopsy. Researchers will c…

This study is testing whether a simple, non-invasive stool test can detect genetic markers in H. pylori bacteria that are linked to a higher risk of stomach cancer. Researchers will compare the stool test's accuracy with a standard risk questionnaire in 15,000 adults aged 40 and …

This study tests whether a blood test that detects tumor DNA (ctDNA) can find colorectal cancer recurrence earlier than standard methods like CEA blood tests or CT scans. Researchers will follow 584 patients with stage I-III colorectal cancer after surgery, monitoring ctDNA every…

This study is testing whether AI-assisted ultrasound and mammography can improve breast cancer screening compared to standard methods. About 16,000 women aged 35-69 will be split into two groups: one gets AI-assisted imaging, the other gets routine screening. The goal is to see i…

This study is testing a new blood test that looks at DNA fragments to find pancreatic neuroendocrine tumors early and to tell them apart from other solid pancreatic tumors. Researchers will enroll 1000 adults with certain pancreatic tumors who haven't had treatment yet. The goal …

This study looks at whether artificial intelligence can help detect breast cancer using standard chest CT scans that don't require a special dye. Researchers will compare the AI's accuracy to mammograms and breast MRIs in 5,000 women. The goal is to see if this approach could off…

This study is testing a new, non-invasive way to screen for stomach cancer using a stool (poop) sample and a simple questionnaire. Researchers at Fudan University will enroll 15,000 adults aged 40 and older to see if the DNA test can find cancer earlier than current methods. Part…

This study checks if a tiny tissue sample taken during a scope (endoscopic biopsy) is as good as a larger sample from surgery for diagnosing stomach cancer. It looks at cancer type, grade, and key markers like HER-2 and MSI. The goal is to see if the less invasive biopsy can repl…

This study tests a cream called Pinoxin to see if it can prevent skin injuries caused by radiation therapy in cancer patients. About 202 adults receiving high-dose radiation will be randomly assigned to use either Pinoxin or a placebo cream. The main goal is to see if Pinoxin low…

This study aims to prevent catheter-related bloodstream infections (CRBSI) in intensive care unit (ICU) patients by implementing a continuous quality improvement program called "ICU-NO CRBSI." Over 8,000 participants from multiple hospitals in China will receive standard care plu…

This study tests whether limiting eating to a 10-hour window each day can lower the chance of developing gestational diabetes in pregnant women at high risk. Researchers will compare this approach to usual eating habits over 3 months in 240 women. The goal is to see if this simpl…

This study tests whether wearing compression or ice gloves and socks can prevent nerve damage caused by the chemotherapy drug UTD1 in people with advanced breast cancer. 324 participants will be randomly assigned to a control group, a compression glove/sock group, or an ice glove…

This phase 3 trial is testing whether the corticosteroid dexamethasone can reduce hand-foot syndrome—a painful skin reaction—caused by liposomal doxorubicin chemotherapy in breast cancer patients. 182 participants will receive either high-dose, standard-dose, or no dexamethasone …

This study tests a digital mind-body therapy that uses music and biofeedback to help women with advanced breast cancer who are undergoing chemotherapy before surgery. The goal is to see if it can reduce sleep problems, anxiety, and depression. Sixty-six participants will be rando…

This study follows 300 Chinese patients with metastatic triple-negative breast cancer to see how they feel during treatment with sacituzumab govitecan or standard chemotherapy. The goal is to measure changes in quality of life and symptoms. Participants must be 18-75 and have HER…

This study tests whether a personalized comfort care plan can help people with advanced esophageal cancer live longer and feel better. About 624 adults whose cancer has spread or returned will receive either standard comfort care or a tailored version that adjusts to their needs.…

This study tests whether two types of PET scans can predict how well a targeted therapy works in people with advanced HER2-negative breast cancer. The therapy, called a TROP2 antibody-drug conjugate, delivers chemotherapy directly to cancer cells. Researchers will scan 45 partici…

This study will follow 3000 people in China with peripheral T-cell lymphoma, a rare and aggressive blood cancer. Researchers will track which treatments patients actually receive and how they fare, aiming to build better prediction tools and understand why some patients relapse. …

This study is looking at whether the bacteria in your gut can predict how well a combination of immunotherapy and chemotherapy works for advanced stomach cancer. Researchers will track 300 patients and check their gut bacteria at several points during treatment. The goal is to fi…

This study follows 3,000 adults aged 40 and older who carry Helicobacter pylori, a common stomach bug. Researchers want to see if people with certain high-risk subtypes of the bacteria develop stomach cancer more often than those with other subtypes or no infection. Participants …

This study looks at how different lung cancer screening habits (like too much, too little, or just right) affect whether the cancer is caught early. About 5,390 newly diagnosed lung cancer patients will share their medical history and screening records. The goal is to find the be…

This study aims to find out which factors help predict whether CAR-T therapy will work in people with relapsed or refractory large B-cell lymphoma. Researchers will look at patient health records, tumor features, and immune system changes in 80 participants. The goal is to better…

This study looks at how common and severe cancer-related fatigue is in people with cancer. Researchers will track up to 1 million Chinese patients to find out what causes fatigue and how it affects their treatment and recovery. The goal is to better understand fatigue so doctors …

This study will follow 2,500 people newly diagnosed with marginal zone B-cell lymphoma to better understand the disease and how different treatments affect it. Researchers will track how long patients live without the cancer getting worse and how well various therapies work. The …

This observational study aims to understand why some ROS1-positive non-small cell lung cancers stop responding to the drug entrectinib. Researchers will analyze tissue or blood samples from 38 patients who have already taken entrectinib as part of their regular care. By using gen…

This study is following 1,000 adults who come to fever clinics with respiratory infections like the flu or pneumonia. Researchers collect data on symptoms, lab tests, and chest scans at the start, then track patients over time to see who gets worse, who recovers quickly, and what…

This study is looking at whether a blood test that detects tiny bits of tumor DNA (called ctDNA) can help doctors more accurately assess how well treatment is working and predict if cancer will come back in people with advanced colorectal cancer. About 497 participants who are re…

This study is creating a large database of 1,000 people with a specific type of pancreatic cancer (KRAS-mutant). Researchers will track how long patients live and how long their cancer stays under control after receiving targeted therapy. The goal is to better understand which tr…

This study looks at how different types of HPV (human papillomavirus) are linked to anal cancer in China. Researchers will collect samples and health information from 300 people with anal cancer to see which HPV types are most common and how the disease affects people. The goal i…

This study is creating a large database to collect information from 2,000 people diagnosed with a rare pancreatic tumor called solid pseudopapillary neoplasm (SPN). The goal is to track patients over time to better understand the disease and improve future treatments. No new trea…

This study is testing whether a special PET scan (HER2-PET) can predict how well the drug T-DXd works in people with advanced breast cancer. About 100 participants with HER2-positive or HER2-low breast cancer will get the scan before treatment. The goal is to see if the scan can …

This study looks at whether using no opioids or fewer opioids during colorectal cancer surgery changes certain immune markers and the behavior of cancer cells. 90 adults having elective surgery will be randomly assigned to one of three anesthesia approaches. The goal is to see if…

This study looks at how the pain and sedation drug remifentanil behaves in low-weight patients in the intensive care unit who are on breathing machines. Researchers will measure drug levels in the blood and check vital signs like blood pressure. The goal is to find the right dose…

This study watches about 1,852 people with esophageal cancer to see how often the cancer spreads to a specific lymph node near the windpipe. Doctors will also look for factors that raise the risk of this spread. The goal is to learn more, not to test a new treatment.

This study tracks 1,100 people with esophageal cancer to see how often the cancer spreads to lymph nodes behind the windpipe. Researchers will also look for factors that raise the risk of this spread. The goal is to better understand the disease and guide future treatment decisio…

This study explores whether age-related differences in blood components can predict how well breast cancer treatment works. Researchers will compare blood samples from younger and older women with HR+HER2- breast cancer before and during therapy. The goal is to find blood markers…

This study looks at whether a person's mental state—like anxiety or depression—can influence how well immunotherapy works for triple-negative breast cancer. About 120 women will receive standard treatment, complete psychological surveys, and give blood and saliva samples. Researc…

This study looks at whether a blood test that detects tumor DNA (ctDNA) can help doctors monitor how well treatment is working in people with stomach cancer. About 600 participants will provide blood samples before and during treatment to see if changes in ctDNA levels predict re…